|
|
|
Insider
Information: |
Rowland Charles A Jr |
Relationship: |
|
City: |
Chadds Ford |
State: |
PA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
607,545 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$2,483,450 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
607,545 |
|
|
Total
Value |
$2,483,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
Percentage
Gain/Loss : |
0.0%
|
-48.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Viropharma Inc |
VPHM |
VP, Chief Financial Of... |
2014-01-24 |
0 |
2008-11-03 |
0 |
Premium* |
|
Endo Health Solutions Inc |
ENDP |
EVP, CFO & Treasurer |
2008-02-21 |
6,699 |
2008-02-21 |
0 |
Premium* |
|
DNIB Upwind Inc |
BIND |
Director |
2016-08-26 |
15,000 |
2016-08-26 |
0 |
Premium* |
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2023-05-16 |
30,000 |
2018-05-29 |
0 |
Premium* |
|
Nabriva Therapeutics AG |
NBRV |
Director |
2022-08-01 |
15,277 |
2018-12-24 |
0 |
Premium* |
|
Blueprint Medicines Corp |
BPMC |
Director |
2021-06-02 |
5,812 |
2019-06-20 |
0 |
Premium* |
|
Orchard Therapeutics Plc |
ORTX |
|
2024-01-24 |
0 |
|
0 |
Premium* |
|
Generation Bio Co. |
GBIO |
|
2023-12-04 |
534,757 |
2020-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2008-11-03 |
4 |
B |
$12.77 |
$102,160 |
D/D |
8,000 |
8,000 |
2.74 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2009-02-26 |
4 |
B |
$4.78 |
$76,522 |
D/D |
16,000 |
24,000 |
2.74 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2011-03-14 |
4 |
OE |
$5.91 |
$280,600 |
D/D |
35,000 |
63,496 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2011-03-14 |
4 |
S |
$18.55 |
$649,950 |
D/D |
(35,000) |
28,496 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2012-03-01 |
4 |
S |
$32.11 |
$2,657,631 |
D/D |
(82,750) |
17,125 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2012-03-01 |
4 |
OE |
$5.91 |
$699,200 |
D/D |
70,000 |
99,875 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2012-03-07 |
4 |
D |
$29.49 |
$374,965 |
D/D |
(12,715) |
35,048 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2012-03-07 |
4 |
OE |
$11.96 |
$374,985 |
D/D |
30,638 |
47,763 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2013-12-18 |
4 |
D |
$49.74 |
$1,249,916 |
D/D |
(25,129) |
60,886 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2013-12-18 |
4 |
OE |
$5.91 |
$453,673 |
D/D |
49,006 |
72,721 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2013-12-27 |
4 |
D |
$49.86 |
$35,101 |
D/D |
(704) |
64,722 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2013-12-27 |
4 |
OE |
$5.91 |
$26,831 |
D/D |
4,540 |
65,426 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2014-01-08 |
4 |
D |
$49.80 |
$321,160 |
D/D |
(6,449) |
87,026 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2014-01-08 |
4 |
OE |
$5.91 |
$273,157 |
D/D |
28,753 |
87,584 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2014-01-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(48,878) |
0 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2014-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
48,878 |
48,878 |
0 |
- |
|
VPHM |
Viropharma Inc |
VP, Chief Financial Officer |
|
2014-01-24 |
4 |
D |
$50.00 |
$4,351,300 |
D/D |
(87,026) |
0 |
0 |
- |
|
VKTX |
Viking Therapeutics, Inc. |
Director |
|
2018-05-29 |
4 |
B |
$5.16 |
$154,800 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
VKTX |
Viking Therapeutics, Inc. |
Director |
|
2023-05-16 |
4 |
AS |
$25.00 |
$1,000,000 |
D/D |
(40,000) |
30,000 |
0 |
% |
|
VKTX |
Viking Therapeutics, Inc. |
Director |
|
2023-05-16 |
4 |
OE |
$1.08 |
$43,200 |
D/D |
40,000 |
70,000 |
0 |
- |
|
ORTX |
Orchard Therapeutics Plc |
Director |
|
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,294 |
|
- |
|
ORTX |
Orchard Therapeutics Plc |
|
|
2024-01-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,294) |
0 |
0 |
- |
|
NBRV |
Nabriva Therapeutics AG |
Director |
|
2018-12-24 |
4 |
B |
$1.31 |
$69,430 |
D/D |
53,000 |
53,000 |
2.39 |
- |
|
NBRV |
Nabriva Therapeutics AG |
Director |
|
2020-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
70,500 |
0 |
- |
|
NBRV |
Nabriva Therapeutics AG |
Director |
|
2021-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
24,550 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|